Rhythm Pharmaceuticals: PWS-Frühdaten sorgen für Kursfantasie – aHO-Entscheid am 20. März 2026 bleibt der Haupttreiber

Kommerziell schon am Markt:  IMCIVREE (Setmelanotid) reduziert das "Alles-oder-nichts"-Risiko klassischer Biotechs  PWS-Impuls mit Vorbehalt:  Vorläufige, offene Phase-2-Daten zeigen "meaningful"...

Rhythm Pharmaceuticals stock hits all-time high at 116.08 USD By Investing.com

Rhythm Pharmaceuticals stock hits all-time high at 116.08 USD

Rythm Pharmaceuticals (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million

Key PointsRythm Pharmaceuticals Chief Technical Officer, Joseph Shulman, recently exercised and sold some stock options. Shulman still held 8,509 shares directly after the trade.These 10 stocks could mint the next wave of millionaires › On November 3, 2025, Chief Technical Officer Joseph Shulman of Rhythm Pharmaceuticals (NASDAQ:RYTM) exercised 9,748 options and immediately disposed of all underlying shares in an open-market transaction, as disclosed in this SEC Form 4 filing.Transaction summar...

Rhythm Pharmaceuticals kurz vor HO-Zulassung – Milliardenmarkt ohne ernsthafte Konkurrenz

Rhythm Pharmaceuticals steht mit Setmelanotid vor der ersten Zulassung für die seltene hypothalamische Adipositas – ein Milliardenmarkt mit kaum Konkurrenz.  Orale und wöchentliche Varianten...

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals (RYTM) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in This Under-the-Radar Weight Loss Stock?

Key PointsRhythm Pharmaceuticals lone approved product currently generates minimal sales.However, recent clinical progress could help change that in the coming years.The biotech is a little risky, but it currently has little competition in its niche.10 stocks we like better than Rhythm Pharmaceuticals › If youre interested in capitalizing on the rapidly growing weight management market, you might naturally consider investing in Eli Lilly and Novo Nordisk. Thats not a bad strategy since these ...

Rhythm Pharmaceuticals CFO Sells 42,120 Shares

Smith Hunter C, Chief Financial Officer of Rhythm Pharmaceuticals(NASDAQ:RYTM), reported mixed transactions totaling 42,120 shares on July 9, 2025, as disclosed in an SEC Form 4 filing, resulting in post-transaction holdings of 116,915 shares.Transaction summaryMetricValueShares Traded42,120Transaction Value$3.4 million (transaction value as of July 11, 2025, per Form 4)Post-Transaction Shares116,915Post-Transaction Value$10.4 million (market value of post-transaction holdings as of July 11, 202...

Rhythm Pharmaceuticals: Auf dem Weg zur Pionierrolle bei seltener Adipositas

Kursfeuerwerk nach Studiendaten:  Rhythm überzeugt mit starken Phase-2-Ergebnissen für eine orale Adipositas-Therapie und katapultiert sich ins Blickfeld institutioneller Investoren.  Markt schafft...

Rhythm Pharmaceuticals prices upsized public offering at $85 per share By Investing.com

Rhythm Pharmaceuticals prices upsized public offering at $85 per share

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Rhythm Pharmaceuticals stock soars on positive Phase 2 obesity drug data By Investing.com

Rhythm Pharmaceuticals stock soars on positive Phase 2 obesity drug data

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know

Rhythm Pharmaceuticals (RYTM) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rhythm gelingt Durchbruch bei seltener Adipositas – Studienerfolg weckt Kursfantasie

• Studienerfolg mit IMCIVREE®:  Rhythm erreicht Durchbruch bei bisher untherapierbarer Adipositas-Form – Zulassungsantrag für 2025 geplant.  • Marktpotenzial & Expansion:  Umsatz-Chance...

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study

Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Company to host conference call on April 7 at 8 a.m. ET Company to host conference call on April 7 at 8 a.m. ET

Rhythm Pharmaceuticals reports preliminary Q4 IMCIVREE revenue $42M

Rhythm Pharmaceuticals: Jährliches Umsatzwachstum von fast 70 % durch Adipositas-Therapie

Viele Unternehmen im Megatrend Biopharmazeutika haben durch Donald Trumps Wahlsieg zum US-Präsidenten einen deutlichen Schub erhalten, doch zahlreiche Aktienkurse korrigierten seitdem wieder. Deshalb...

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of results from its Phase 3 VENTURE trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in children between the ages of 2 and younger than 5 years old with Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), p...

Hungerkontrolle: Der Kampf gegen Adipositas

Rhythm Pharmaceuticals ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung innovativer Therapien zur Behandlung seltener genetischer Adipositasstörungen konzentriert. Das Hauptaugenmerk...

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences:

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

BOSTON and LONDON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) and Axovia Therapeutics Ltd. today announced a joint research collaboration designed to advance the understanding of Bardet-Biedl syndrome (BBS).

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 6, 2024 to report its second quarter 2024 financial results and provide a corporate update.

Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Earnings Call Transcript

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on April 11, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 31,220 shares of its common stock to eight new employees, consisting of inducement stock options to pu...

Rhythm Pharmaceuticals CTO sells shares worth over $735k By Investing.com

Rhythm Pharmaceuticals CTO sells shares worth over $735k

Rhythm Pharmaceuticals executive sells shares worth over $700k By Investing.com

Rhythm Pharmaceuticals executive sells shares worth over $700k

Rhythm Pharmaceuticals CFO sells shares worth over $600k By Investing.com

Rhythm Pharmaceuticals CFO sells shares worth over $600k